Previous studies have leveraged integrative genomic analyses to elucidate the genomic and epigenomic drivers of mCRPC, such as the occurrence of mutations in the AR region, genes associated with RB1 biallelic inactivation, and the presence of hypomethylated regions in prostate cancer-specific genes13–15. This evidence concerns the gene AR and prostate carcinoma.